Stratasys has announced a joint development and commercialization agreement for the biofabrication of human tissues and organs with CollPlant Biotechnologies. The cooperation will include the combination of a bioprinter based on the Stratasys programmable photopolymerization (P3) technology and a bioink based on rhCollagen CollPlant. A first project was also announced, focusing on the development of an industrial-scale solution for a regenerative breast implant program.
Based on the new Stratasys 3D bioprinting system and CollPlant bioinks, state-of-the-art breast implants will be developed to regenerate a person’s natural breast tissue without triggering an immune response. According to the companies, the resulting product is to be a potentially revolutionary alternative to both aesthetic and reconstructive procedures. Stratasys and CollPlant will mutually promote their bioprinting products and offer bioprinters and bioinks to their customers.
According to the ISAPS International Survey on Aesthetic/Cosmetic Procedures published in 2021, breast reconstruction and augmentation procedures are the second most frequently performed plastic surgery procedure. Regenerative breast implants showed progressive stages of tissue regeneration through the formation of maturing connective tissue and neovascular network within the implants three months after implantation. So far, no adverse effects have been reported.
Based on these positive results, CollPlant plans to launch another large animal study using commercial-sized implants in the second half of 2023 to support further human trials and future commercialization of the product.
Source: Stratasys press materials